Alimera Sciences Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 158

Employees

  • Stock Symbol
  • ALIM

Stock Symbol

  • Share Price
  • $3.34
  • (As of Wednesday Closing)

Alimera Sciences General Information

Description

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 6310 Town Square
  • Suite 400
  • Alpharetta, GA 30005
  • United States
+1 (678) 000-0000

Alimera Sciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alimera Sciences Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.34 $3.50 $1.30 - $4.38 $175M 52.4M 104K -$1.65

Alimera Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 282,605 76,841 76,423 83,418
Revenue 68,477 54,129 59,029 50,820
EBITDA (6,599) (9,492) 4,058 2,649
Net Income (20,131) (18,107) (4,372) (5,339)
Total Assets 154,192 42,602 58,520 50,855
Total Debt 64,415 45,097 43,569 44,503
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alimera Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatme
Pharmaceuticals
Alpharetta, GA
158 As of 2022
00000
000000000 00 00000

000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
Watertown, MA
000 As of 0000
00000
00000000 00000

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000000000000
Leuven, Belgium
00 As of 0000
0000
000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alimera Sciences Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EyePoint Pharmaceuticals Corporation Watertown, MA 000 00000 00000000 00000
Oxurion Corporation Leuven, Belgium 00 0000 000000000 0000
Ocuphire Pharma Formerly VC-backed Farmington Hills, MI 0 00000 00000000 00000
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
Genentech Formerly VC-backed South San Francisco, CA 00000 00.000 00000000000 00.000
You’re viewing 5 of 41 competitors. Get the full list »

Alimera Sciences Patents

Alimera Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11400070-B2 Methods of treating retinal diseases Active 03-May-2018 000000000 00
EP-3787749-A1 Methods of treating retinal diseases Pending 03-May-2018 000000000
US-20190336466-A1 Methods of treating retinal diseases Active 03-May-2018 000000000 0
EP-3787749-A4 Methods of treating retinal diseases Pending 03-May-2018 000000000 0
US-8404270-B2 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Inactive 23-Dec-2009 A61K9/0051 0
To view Alimera Sciences’s complete patent history, request access »

Alimera Sciences Executive Team (18)

Name Title Board Seat Contact Info
Richard Eiswirth Jr. President, Chief Executive Officer & Board Member
Philip Ashman Ph.D President
David Holland Chief Marketing Officer, Marketing & Founder
David Dyer MD Chief Retina Specialist
Antonio Cutino Vice President, Medical Affairs
You’re viewing 5 of 18 executive team members. Get the full list »

Alimera Sciences Board Members (19)

Name Representing Role Since
Adam Morgan Velan Capital Board Member 000 0000
Garheng Kong Ph.D Self Board Member 000 0000
John Snisarenko Self Board Member 000 0000
Mark Brooks Self Board Member 000 0000
Michael Kaseta Self Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Alimera Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alimera Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Alimera Sciences’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »